Overview
Arthrodynamic Holdings, LLC has built upon the well established medical benefits of hyaluronic acid (sodium hyaluronate). Our lead product, ADH-01, compliments hyaluronic acid by combining it with chondroitin sulfate and n-acetyl-d-glucosamine. Our technology was first developed in veterinary medicine, and launched as Polyglycan® for performance equine athletes which succumb to various joint related injuries. Based on the success in veterinary medical orthopedics, we are now focused on the development of our human product, ADH-01, for orthopedic and urogenital applications. The following describes our company’s lead orthopedic product.
ADH-01 Orthopedic Product Summary
Contents: Sterile, viscoelastic solution of purified, Sodium Hyaluronate, Chondroitin Sulfate and N-Acetyl-D-Glucosamine
pH: 5.7-7.3
Volume: 10mL injection vial
Anticipated Dose Schedule: Single intra-articular injection every 6-12 months
Anticipated Claims: For the management of pain associated with knee osteoarthritis
Manufacture: ADH-01 will be produced at a FDA registered Contract Development and Manufacturing Organization (CDMO) with fully integrated analytical, formulation development, and pharmaceutical manufacturing services in an ISO Class 5, 7 and 8 environment.
Video Explaining Hyaluronic Acid*
Description of ADH-01 Viscoelastic Composition
- Sodium Hyaluronate is one of the primary viscoelastic constituents of synovial fluid and provides the primary means for establishing viscosity in the formulation, providing lubrication and shock absorbing capability, thus reducing friction between articular surfaces.
- Chondroitin is a complex carbohydrate, and serves as a scaffold which provides shock and water-absorbing capabilities which reduce intra-articular surface friction during movement. Within chondroitin are tightly packed sulfate groups. Chondroitin 4-sulfate and chondroitin 6-sulfate are GAGs and differ structurally by the position of the monosaccharide. In general, chondroitin helps to form a barrier that can withstand compression and shock that can damage the tissue.
- N-acetyl-D-glucosamine (NADG) is primarily included in the formulation as a carrier to maintain proper viscosity. Glucosamine is naturally found in the cartilage of joints and as the cartilage deteriorates with age it loses its ability to produce glucosamine which results in increased friction between articular surfaces. N-Acetyl-D-Glucosamine in ADH-01 supplements the loss of endogenous glucosamine by providing a cushioning effect between cartilages.
ADH-01 Compared to Other Key Orthopedic Viscoelastics
The existing key comparators are comprised of hyaluronic acid (sodium hyaluronate). ADH-01 expands upon the strong track record of hyaluronic acid, and combines HA with NADG and CS proposing to be the most comprehensive viscoelastic formulation.
Relevant Publications and References
R.R. Bannuru, N.S. Natov, U.R. Dasi, C.H. Schmid, T.E. McAlindon. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis – meta-analysis. Osteoarthritis and Cartilage 19 (2011) 611-619.
Synvisc-One is a trademark of Genzyme Corporation; Gel-One is a trademark of Seikagaku Kogyo Kabushiki Kaisha Corp.; Hyalgan is a trademark of Fidia S.P.A.; MonoVisc is a trademark of Anika Therapeutics, Inc.; Supartz trademark of Seikagaku Corp., Polyglycan is a trademark of Arthrodynamic Technologies, Inc. [trademark attribution is based on United States Patent and Trademark Office TESS search].
*Arthrodynamic Holdings, LLC has embedded this video for educational purposes only and is not responsible for its content.